Search Orphan Drug Designations and Approvals
-
| Generic Name: | chemically synthesized double-stranded oligonucleotide directed against C3 messenger RNA |
|---|---|
| Date Designated: | 10/16/2025 |
| Orphan Designation: | treatment of complement 3 glomerulopathy |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Sanegene Bio USA Inc. 1 Broadway, 14th Floor Cambridge, Massachusetts 02142 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







